Fidia announces the FDA Orphan Drug designation for ONCOFID®-P for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos
· ONCOFID®-P is an innovative conjugation of the anticancer drug paclitaxel (taxol) with hyaluronic acid (HA).
